Nektar PEGylation technology is also used in eight additional approved partnered products in the U.S. or Europe today, including Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.
Nektar Therapeutics is a biopharmaceutical company that develops and enables differentiated therapeutics with its industry-leading PEGylation and pulmonary drug development technology platforms. Nektar PEGylation and pulmonary technology, expertise, and manufacturing capabilities have enabled nine approved products for partners, which include the world's leading pharmaceutical and biotechnology companies. Nektar is also developing its own product candidates by applying its PEGylation and pulmonary technology platforms to existing medicines with the objective to enhance performance, such as improving efficacy, safety and compliance.
This press release contains forward-looking statements regarding the
potential of the company's PEGylation technology platform and NKTR-118.
These forward-looking statements involve important risks and uncertainties,
including but not limited to: (i) clinical trials for NKTR-118 are long,
expensive and uncertain processes, (ii) because the NKTR-118 product
development program is in the early phases of clinical development, the
risk of failure is high and can occur at any stage of development, (iii)
the company may fail to obtain regulatory approval of NKTR-118, (iv)
potential competition from approved drugs or drugs under development that
may be safe and effective for the same indication as that targeted by
NKTR-118, and (v) the company's patent applications for NKTR-118 may fail
to issue; patents that have issued may not be enforceable; or unanticipated
intellectual property licenses from third parties may be required in the
|SOURCE Nektar Therapeutics|
Copyright©2007 PR Newswire.
All rights reserved